// +author:l agarwal +author:agarwal 
var _ajax_res = {
  hits: 32,

  first: 0,

  results: [

{userid:"frank.troxell", "refid":"96","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Genome Sequence of Rhizobium lupini HPC(L) Isolated from Saline Desert Soil, Kutch (Gujarat)","year":"2013","author":"L Agarwal, H J Purohit","journal":"Genome Announc","volume":"1","number":"1","pages":"","month":"","doi":"10.1128\/genomeA.00071-12","pubmed":"23405347","pdflink":"","urllink":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23405347","abstract":"The Rhizobium lupini strain HPC(L) was isolated from saline desert soil. It grows on minimal media supplemented with CaCO(3) as a carbon source. It can also grow under both oligotrophic and heteroptrophic conditions. We report the annotated genome sequence of this strain in a 5.27-Mb scaffold.","note":"Agarwal, Leena xD;Purohit, Hemant J xD;eng xD;2013\/02\/14 06:00 xD;Genome Announc. 2013 Jan;1(1). pii: e00071-12. doi: 10.1128\/genomeA.00071-12. Epub 2013 Jan 15.","tags":"DNA Sequencing, Small Genome Sequencing, de novo, Bacteria, Ion PGM,\t Microbiology, PGM,Genome, DNA Sequencing,Small Genome Sequencing de novo,bacteria,Ion PGM, Microbiology","publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"2169-8287 (Electronic)","isi":"","key":"Agarwal2013","howpublished":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23405347"}
,

{userid:"Lars.Ronnstrand", "articletype":"article","pages":"22460-8","author":"S Agarwal, J U Kazi, L R\u00f6nnstrand","year":"2013","title":"Phosphorylation of the Activation Loop Tyrosine 823 in c-Kit Is Crucial for Cell Survival and Proliferation","month":"","journal":"J Biol Chem","publisher":"","volume":"288","number":"31","note":"Agarwal, Shruti xD;Kazi, Julhash U xD;Ronnstrand, Lars xD;eng xD;2013\/06\/28 06:00 xD;J Biol Chem. 2013 Aug 2;288(31):22460-8. doi: 10.1074\/jbc.M113.474072. Epub 2013 Jun 26.","tags":"","booktitle":"","editor":"","abstract":"The receptor tyrosine kinase c-Kit, also known as the stem cell factor receptor, plays a key role in several developmental processes. Activating mutations in c-Kit lead to alteration of these cellular processes and have been implicated in many human cancers such as gastrointestinal stromal tumors, acute myeloid leukemia, testicular seminomas and mastocytosis. Regulation of the catalytic activity of several kinases is known to be governed by phosphorylation of tyrosine residues in the activation loop of the kinase domain. However, in the case of c-Kit phosphorylation of Tyr-823 has been demonstrated to be a late event that is not required for kinase activation. However, because phosphorylation of Tyr-823 is a ligand-activated event, we sought to investigate the functional consequences of Tyr-823 phosphorylation. By using a tyrosine-to-phenylalanine mutant of tyrosine 823, we investigated the impact of Tyr-823 on c-Kit signaling. We demonstrate here that Tyr-823 is crucial for cell survival and proliferation and that mutation of Tyr-823 to phenylalanine leads to decreased sustained phosphorylation and ubiquitination of c-Kit as compared with the wild-type receptor. Furthermore, the mutated receptor was, upon ligand-stimulation, quickly internalized and degraded. Phosphorylation of the E3 ubiquitin ligase Cbl was transient, followed by a substantial reduction in phosphorylation of downstream signaling molecules such as Akt, Erk, p38, Shc, and Gab2. Thus, we propose that activation loop tyrosine 823 is crucial for activation of both the MAPK and PI3K pathways and that its disruption leads to a destabilization of the c-Kit receptor and decreased survival of cells.","address":"","school":"","issn":"","doi":"10.1074\/jbc.M113.474072","isi":"","pubmed":"","key":"Agarwal2013","howpublished":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23803604","urllink":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23803604","refid":114}
,

{userid:"Lars.Ronnstrand", "refid":"126","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Src-Like Adaptor Protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling","year":"2014","author":"J.U. Kazi, S. Agarwal, J. Sun, E. Bracco, L.  R\u00f6nnstrand","journal":"J Cell Sci ","volume":"127","number":"","pages":"653-62","month":"","doi":"10.1242\/jcs.140590","pubmed":"24284075","pdflink":"","urllink":"","abstract":"","note":"","tags":"","weight":126}
,

{userid:"manivannan.sethuraman", "refid":1011,"repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"GREEN SYNTHESIS OF SILVER NANOPARTICLES USING CALLUS EXTRACT OF\r\nCAPSICUM ANNUUM L. AND THEIR ACTIVITY AGAINST MICROORGANISMS","year":"2014","author":"PRITI AGARWAL, VINOD KUMAR BAIRWA, SUMITA KACHHWAHA & S. L. KOTHARI","journal":"International Journal of Nanotechnology and Application (IJNA)","volume":"4","number":"5","pages":"1-8","month":"Oct","doi":"","pubmed":"","pdflink":"http:\/\/www.tjprc.org\/view-archives.php?year=2014&id=6&jtype=2&page=2","urllink":"","abstract":"Several biological methods for the production of silver nanoparticles (Ag-NPs) are available due to their multiple\r\napplications. Biosynthesis of silver nanoparticles using callus extract of Capsicum annuum offers an extracellular synthesis\r\nof nanoparticles. It is eco-friendly and cost effective approach so it can be an economic and efficient alternative way for\r\nthe synthesis of nanoparticles on large scale. In this study the biosynthesis of silver nanoparticles using callus extract of\r\nCapsicum annuum and antimicrobial activities has been reported. Silver nanoparticles were synthesized by bioreduction of\r\nsilver nitrate (AgNO3) solution with callus extract of C. annuum and characterized using UV-Vis absorption\r\nspectrophotometer, Photoluminescence, FTIR, XRD, SEM, and EDS. A mixed phase, cubic and hexagonal, with the\r\naverage particle size of 15 nm, SNPs thus synthesized, were evaluated for their antimicrobial activity.","note":"","tags":"Silver Nanoparticles, Anti-Tubercular Agent, Callus Extract, Capsicum annuum, Bio Reduction, Antimicrobial Properties","weight":1011}
,

{userid:"Lars.Ronnstrand", "refid":"135","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V","year":"2015","author":"S Agarwal, JU Kazi, S Mohlin, S P\u00e5hlman and L R\u00f6nnstrand","journal":"Oncogene ","volume":"34","number":"35","pages":"4581-4590","month":"","doi":"10.1038\/onc.2014.383","pubmed":"    25435369","pdflink":"http:\/\/www.nature.com\/onc\/journal\/v34\/n35\/full\/onc2014383a.html","urllink":"","abstract":"Oncogenic c-Kit mutations have been shown to display ligand-independent receptor activation and cell proliferation. A substitution of aspartate to valine at amino acid 816 (D816V) is one of the most commonly found oncogenic c-Kit mutation and is found in more than 90% of cases of mastocytosis and less commonly in germ cell tumors, core-binding factor acute myeloid leukemia and mucosal melanomas. The mechanisms by which this mutation leads to constitutive activation and transformation are not fully understood. Previous studies have shown that the D816V mutation causes a structural change in the activation loop resulting in weaker binding of the activation loop to the juxtamembrane domain. In this paper we have investigated the role of Y823, the only tyrosine residue in the activation loop, and its role in oncogenic transformation by c-Kit\/D816V by introducing the Y823F mutation. Although dispensable for the kinase activity of c-Kit\/D816V, the presence of Y823 was crucial for cell proliferation and survival. Furthermore, mutation of Y823 selectively down-regulates the Ras\/Erk and Akt pathways as well as the phosphorylation of STAT5 and reduces the transforming capacity of the D816V\/c-Kit in vitro. We further show that mice injected with cells expressing c-Kit\/D816V\/Y823F display significantly reduced tumor size as well as tumor weight compared to controls. Finally, microarray array analysis, comparing Y823F\/D816V cells with cells expressing c-Kit\/D816V, demonstrate that mutation of Y823 causes up-regulation of pro-apoptotic genes whereas genes of survival pathways are down-regulated. Thus, phosphorylation of Y823 is not necessary for kinase activation, but essential for the transforming ability of the c-Kit\/D816V mutant.","note":"","tags":"c-Kit, D816V, Y823F, activation loop, tyrosine phosphorylation, signaling, transformation, cancer","weight":135}
,

{userid:"Lars.Ronnstrand", "articletype":"article","pages":"1852-60","author":"J U Kazi, M Vaapil, S Agarwal, E Bracco, S P\u00e5hlman, L R\u00f6nnstrand","year":"2013","title":"The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling","month":"","journal":"Cell Signal","publisher":"","volume":"25","number":"9","note":"Kazi, Julhash U xD;Vaapil, Marica xD;Agarwal, Shruti xD;Bracco, Enrico xD;Pahlman, Sven xD;Ronnstrand, Lars xD;eng xD;Research Support, Non-U.S. Gov't xD;England xD;2013\/05\/28 06:00 xD;Cell Signal. 2013 Sep;25(9):1852-60. doi: 10.1016\/j.cellsig.2013.05.016. Epub 2013 May 21.","tags":"","booktitle":"","editor":"","abstract":"Type III receptor tyrosine kinases (RTKs), FLT3 and c-Kit play important roles in a variety of cellular processes. A number of SH2-domain containing proteins interact with FLT3 and c-Kit and regulate downstream signaling. The SH2-domain containing non-receptor protein tyrosine kinase CSK is mainly studied in the context of regulating Src family kinases. Here we present an additional role of this kinase in RTK signaling. We show that CSK interacts with FLT3 and c-Kit in a phosphorylation dependent manner. This interaction is facilitated through the SH2-domain of CSK. Under basal conditions CSK is mainly localized throughout the cytosolic compartment but upon ligand stimulation it is recruited to the inner side of cell membrane. CSK association did not alter receptor ubiquitination or phosphorylation but disrupted downstream signaling. Selective depletion of CSK using siRNA, or inhibition with CSK inhibitor, led to increased phosphorylation of Akt and Erk, but not p38, upon FLT3 ligand (FL) stimulation. Stem cell factor (SCF)-mediated Akt and Erk activation was also elevated by CSK inhibition. However, siRNA mediated CSK knockdown increased SCF stimulated Akt phosphorylation but decreased Erk phosphorylation. CSK depletion also significantly increased both FL- and SCF-induced SHC, Gab2 and SHP2 phosphorylation. Furthermore, CSK depletion contributed to oncogenic FLT3- and c-Kit-mediated cell proliferation, but not to cell survival. Thus, the results indicate that CSK association with type III RTKs, FLT3 and c-Kit can have differential impact on receptor downstream signaling.","address":"","school":"","issn":"","doi":"10.1016\/j.cellsig.2013.05.016","isi":"","pubmed":"","key":"Kazi2013d","howpublished":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23707526","urllink":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23707526","refid":122}
,

{userid:"Sekretariat", "articletype":"article","pages":"345-356","author":"L M Ruilope, R Agarwal, S D Anker, G L Bakris, G Filippatos, C Nowack, P Kolkhof, A Joseph, N Mentenich, B Pitt, Figaro-Dkd study investigators","year":"2019","title":"Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial","month":"","journal":"Am J Nephrol","publisher":"","volume":"50","number":"5","note":"Ruilope, Luis M  ;Agarwal, Rajiv  ;Anker, Stefan D  ;Bakris, George L  ;Filippatos, Gerasimos  ;Nowack, Christina  ;Kolkhof, Peter  ;Joseph, Amer  ;Mentenich, Nicole  ;Pitt, Bertram  ;eng  ;Switzerland  ;Am J Nephrol. 2019;50(5):345-356. doi: 10.1159\/000503712. Epub 2019 Oct 30.","tags":"THAC,Website_BIH,2019","booktitle":"","editor":"","abstract":"BACKGROUND: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. PATIENTS AND METHODS: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >\/=25 mL\/min\/1.73 m2 and albuminuria (urinary albumin-to-creatinine ratio >\/=30 to <\/=5,000 mg\/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. CONCLUSIONS: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. TRIAL REGISTRATION: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.","address":"","school":"","issn":"1421-9670 (Electronic)  ;0250-8095 (Linking)","doi":"10.1159\/000503712","isi":"","pubmed":"","key":"THACp","howpublished":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31665733","urllink":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31665733","refid":16610,"weight":16610}
,

{userid:"qasimhusain1", "articletype":"article","pages":"1102-1105","author":"Krystal L Tomei, Meghan M Nahass, Qasim Husain, Nitin Agarwal, Smruti K Patel, Peter F Svider, Jean Anderson Eloy, James K Liu","year":"2014","title":"A gender-based comparison of academic rank and scholarly productivity in academic neurological surgery.","month":"Jul","journal":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","publisher":"","volume":"21","number":"7","note":"","tags":"Accreditation,American Medical Association,Bibliometrics,Biomedical Research,Female,Humans,Male,Neurosurgery,Sex Characteristics,United States","booktitle":"","editor":"","abstract":"The number of women pursuing training opportunities in neurological surgery has increased, although they are still underrepresented at senior positions relative to junior academic ranks. Research productivity is an important component of the academic advancement process. We sought to use the h-index, a bibliometric previously analyzed among neurological surgeons, to evaluate whether there are gender differences in academic rank and research productivity among academic neurological surgeons. The h-index was calculated for 1052 academic neurological surgeons from 84 institutions, and organized by gender and academic rank. Overall men had statistically higher research productivity (mean 13.3) than their female colleagues (mean 9.5), as measured by the h-index, in the overall sample (p<0.0007). When separating by academic rank, there were no statistical differences (p>0.05) in h-index at the assistant professor (mean 7.2 male, 6.3 female), associate professor (11.2 male, 10.8 female), and professor (20.0 male, 18.0 female) levels based on gender. There was insufficient data to determine significance at the chairperson rank, as there was only one female chairperson. Although overall gender differences in scholarly productivity were detected, these differences did not reach statistical significance upon controlling for academic rank. Women were grossly underrepresented at the level of chairpersons in this sample of 1052 academic neurological surgeons, likely a result of the low proportion of females in this specialty. Future studies may be needed to investigate gender-specific research trends for neurosurgical residents, a cohort that in recent years has seen increased representation by women. ","address":"","school":"","issn":"1532-2653","doi":"10.1016\/j.jocn.2013.11.006","isi":"","pubmed":"24411320","key":"Tomei2014","howpublished":"","urllink":"","refid":20,"weight":20}
,

{userid:"Sekretariat", "articletype":"article","pages":"333-344","author":"G L Bakris, R Agarwal, S D Anker, B Pitt, L M Ruilope, C Nowack, P Kolkhof, A C Ferreira, P Schloemer, G Filippatos, Fidelio- D K D study investigators on behalf of the","year":"2019","title":"Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial","month":"","journal":"Am J Nephrol","publisher":"","volume":"50","number":"5","note":"Bakris, George L  ;Agarwal, Rajiv  ;Anker, Stefan D  ;Pitt, Bertram  ;Ruilope, Luis M  ;Nowack, Christina  ;Kolkhof, Peter  ;Ferreira, Anna C  ;Schloemer, Patrick  ;Filippatos, Gerasimos  ;eng  ;Switzerland  ;Am J Nephrol. 2019;50(5):333-344. doi: 10.1159\/000503713. Epub 2019 Oct 25.","tags":"Website_BIH,2019,THAC","booktitle":"","editor":"","abstract":"BACKGROUND: Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalemia. However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. METHODS: The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease -(FIDELIO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important renal and CV outcomes in T2D patients with CKD. FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 5.5 years. FIDELIO-DKD randomized 5,734 patients with an estimated glomerular filtration rate (eGFR) >\/=25-<75 mL\/min\/1.73 m2 and albuminuria (urinary albumin-to-creatinine ratio >\/=30-<\/=5,000 mg\/g). The study has at least 90% power to detect a 20% reduction in the risk of primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of kidney failure, a sustained decrease of eGFR >\/=40% from baseline over at least 4 weeks, or renal death. CONCLUSION: FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.","address":"","school":"","issn":"1421-9670 (Electronic)  ;0250-8095 (Linking)","doi":"10.1159\/000503713","isi":"","pubmed":"","key":"THACc","howpublished":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31655812","urllink":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31655812","refid":16481,"weight":16481}
,

{userid:"amvinodkumar", "articletype":"article","pages":"1902-1908","author":"D O Kataria, A K Sinha, J J Das, N Madhavan, P Sugathan, L T Baby, I Mazumdar, R Singh, C V K Baba, Y K Agarwal, A M Vinodkumar, K M Varier","year":"1997","title":"One- and two-nucleon transfer in the Si-28+Zn-68 system at energies below the Coulomb barrier","month":"OCT","journal":"PHYSICAL REVIEW C","publisher":"","volume":"56","number":"4","note":"","tags":"","booktitle":"","editor":"","abstract":"Excitation functions for one-and two-nucleon transfer in Si-28 + Zn-68 system have been measured at energies below the Coulomb barrier. The experiment was carried out by detecting the forward recoiling targetlike nuclei using the recoil mass separator, HIRA. With a pulsed beam, the time-of-flight of the recoils was measured and used to resolve the M\/q ambiguity. This enabled the determination of the two-nucleon transfer yields. The role of one-and two-nucleon transfer in the sub-barrier fusion cross-section enhancement has been investigated. It turns out that the coupling of the positive e-value two-neutron transfer channel results in a significant contribution to the enhancement. Coupling to both the transfer and the inelastic channels is able to explain the observed enhancement.","address":"","school":"","issn":"0556-2813","doi":"10.1103\/PhysRevC.56.1902","isi":"","pubmed":"","key":"ISI:A1997YC72900025","howpublished":"","urllink":"","refid":66,"weight":66}
  ]
}

;
ajaxResultsLoaded(_ajax_res);